Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH
Epistemonikos ID: e12840994d7ed208157ac0fa2992a5aec1f26b55
First added on: May 27, 2020